Hepatitis Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Hepatitis Treatment Market By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Others), By Drug Type (Vaccines, Anti-Viral Drugs, Interferons, Others), By Route of Administration (Oral , Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global hepatitis treatment market size was valued at USD 4.1 Billion in 2020 and expected to reach USD 6.3 Billion by 2026, at a CAGR of 5.6% during the forecast period. Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies. Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the hepatitis treatment market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the hepatitis treatment market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of hepatitis treatment market over the forecast period.

Hepatitis Treatment Market

MARKET SUMMARY
-
5.6% CAGR
  • Study Period– 2021 – 2026
  • Base Year– 2020
  • CAGR– 5.6%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Hepatitis Treatment Market

  • The report on global hepatitis treatment market gives historical, current and future market sizes (US$ Bn) on the disease type, drug type, route of administration, distribution channel, and region.
  • hepatitis treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Market Key Players
  • Hoffmann- La Roche Ltd.
  • Gilead Sciences
  • Novartis AG
  • Bristol-Myers Squibb
  • GlaxoSmithKline, plc.
  • Merck and Co, Inc.
Drivers And Restraints

Hepatitis Treatment Market

Global hepatitis treatment market is driven by rising in the prevalence of various types of hepatitis infections. According to WHO in 2015, approximately 257 Mn hepatitis B, 71 Mn hepatitis C cases, and approximately 15 Mn hepatitis D cases observed around the globe. Majority of the local and international market players are actively seeking to develop newer drugs and vaccines for the treatment of hepatitis infection. Moreover, strong product pipeline for hepatitis treatment expected to upsurge the market revenue over the forecast timeframe. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies adopted by the market players for dominating the hepatitis treatment market. For instance, in June 2016, FDA approved Epclusa manufactured by Gilead Sciences, Inc. used in the treatment of chronic hepatitis C virus infection. Moreover, in May 2017, Eiger Biopharmaceuticals filed investigational new drug application with FDA for Lambda (pegylated interferon lambda 1a) for the treatment of hepatitis D.


North-America got significant share

Hepatitis Treatment Market

Geographically, global hepatitis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North Americahepatitis treatment market is poised to grow due to increase in the prevalence of hepatitis infection, the rise in R&D activities for the innovation of new drugs, an increase in healthcare expenditure in the region. Europehepatitis treatment market expected to exhibit lucrative growth owing to rise in prevalence of hepatitis due to change in lifestyle, increase in awareness about the hepatitis treatment, and adoption of newer drugs and vaccines are propelling the market. Asia Pacifichepatitis treatment market is growing due to increase in the geriatric population in India, China, and Japan, the rise in healthcare expenditure, and launching of generic drugs into the market. Latin America hepatitis treatment market is driven by an increase in hepatitis C infection, launching of newer products into the market, and increase in the awareness about hepatitis treatment. Middle East and Africahepatitis treatment market’s growth is attributed to economic growth, increase in the prevalence of hepatitis infection in African countries, and expansion of businesses by market players in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In September 2017, China Food and Drug Administration approved Gilead’s Sovaldi (Sofosbuvir) used in the treatment of chronic HCV infection

Key

Key Features of the Report

Hepatitis Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Hoffmann- La Roche Ltd. (Switzerland)
  • Gilead Sciences (U.S.)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb (U.S)
  • GlaxoSmithKline, plc.
  • Merck and Co, Inc. (U.S)
  • Johnson & Johnson Services, Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Novira Therapeutics Inc. (U.S.)
  • Eiger Biopharmaceuticals (U.S.)

Description

The global hepatitis treatment market size was valued at USD 4.1 Billion in 2020 and expected to reach USD 6.3 Billion by 2026, at a CAGR of 5.6% during the forecast period. Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies. Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the hepatitis treatment market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the hepatitis treatment market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of hepatitis treatment market over the forecast period.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX